Literature DB >> 24065278

Template-constrained cyclic sulfopeptide HIV-1 entry inhibitors.

Jonathan G Rudick1, Meg M Laakso, Ashley C Schloss, William F DeGrado.   

Abstract

Template-constrained cyclic sulfopeptides that inhibit HIV-1 entry were rationally designed based on a loop from monoclonal antibody (mAb) 412d. A focused set of sulfopeptides was synthesized using Fmoc-Tyr(SO3DCV)-OH (DCV = 2,2-dichlorovinyl). Three cyclic sulfopeptides that inhibit entry of HIV-1 and complement the activity of known CCR5 antagonists were identified.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24065278      PMCID： PMC3889485          DOI： 10.1039/c3ob41395k

Source DB:  PubMed          Journal:  Org Biomol Chem        ISSN： 1477-0520            Impact factor:   3.876


  33 in total

1.  HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use.

Authors:  Alexandra Trkola; Shawn E Kuhmann; Julie M Strizki; Elizabeth Maxwell; Tom Ketas; Tom Morgan; Pavel Pugach; Serena Xu; Lisa Wojcik; Jayaram Tagat; Anandan Palani; Sherry Shapiro; John W Clader; Stuart McCombie; Gregory R Reyes; Bahige M Baroudy; John P Moore
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-08       Impact factor: 11.205

2.  A strategy for the synthesis of sulfated peptides.

Authors:  Travis Young; Laura L Kiessling
Journal:  Angew Chem Int Ed Engl       Date:  2002-09-16       Impact factor: 15.336

3.  Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry.

Authors:  M Farzan; T Mirzabekov; P Kolchinsky; R Wyatt; M Cayabyab; N P Gerard; C Gerard; J Sodroski; H Choe
Journal:  Cell       Date:  1999-03-05       Impact factor: 41.582

4.  Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.

Authors:  Mike Westby; Caroline Smith-Burchnell; Julie Mori; Marilyn Lewis; Michael Mosley; Mark Stockdale; Patrick Dorr; Giuseppe Ciaramella; Manos Perros
Journal:  J Virol       Date:  2006-12-20       Impact factor: 5.103

5.  Facile solid-phase synthesis of sulfated tyrosine-containing peptides: total synthesis of human big gastrin-II and cholecystokinin (CCK)-39.

Authors:  K Kitagawa; C Aida; H Fujiwara; T Yagami; S Futaki; M Kogire; J Ida; K Inoue
Journal:  J Org Chem       Date:  2001-01-12       Impact factor: 4.354

6.  A comprehensive approach to the synthesis of sulfate esters.

Authors:  Levi S Simpson; Theodore S Widlanski
Journal:  J Am Chem Soc       Date:  2006-02-08       Impact factor: 15.419

7.  Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120.

Authors:  Hyeryun Choe; Wenhui Li; Paulette L Wright; Natalya Vasilieva; Miro Venturi; Chih-Chin Huang; Christoph Grundner; Tatyana Dorfman; Michael B Zwick; Liping Wang; Eric S Rosenberg; Peter D Kwong; Dennis R Burton; James E Robinson; Joseph G Sodroski; Michael Farzan
Journal:  Cell       Date:  2003-07-25       Impact factor: 41.582

Review 8.  Tyrosine sulfation: an increasingly recognised post-translational modification of secreted proteins.

Authors:  Martin J Stone; Sara Chuang; Xu Hou; Menachem Shoham; John Z Zhu
Journal:  N Biotechnol       Date:  2009-06       Impact factor: 5.079

9.  Efficient solid-phase synthesis of sulfotyrosine peptides using a sulfate protecting-group strategy.

Authors:  Ahmed M Ali; Scott D Taylor
Journal:  Angew Chem Int Ed Engl       Date:  2009       Impact factor: 15.336

Review 10.  Novel approaches to inhibit HIV entry.

Authors:  Chukwuka A Didigu; Robert W Doms
Journal:  Viruses       Date:  2012-02-21       Impact factor: 5.048
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.